The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Artemenko A.R.

Moskovskaia meditsinskaia akademiia im. I.M. Sechenova

Kurenkov A.L.

Nauchnyĭ tsentr zdorov'ia deteĭ RAMN

Nikitin S.S.

GU NII OPiPF RAMN, Moskva

Treatment of chronic migraine

Authors:

Artemenko A.R., Kurenkov A.L., Nikitin S.S.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2011;111(5): 85‑89

Read: 1510 times

Download PDF (RU)
Contact the author
Table of contents

TREATMENT OF CHRONIC MIGRAINE
TREATMENT OF CHRONIC MIGRAINE

To cite this article:

Artemenko AR, Kurenkov AL, Nikitin SS. Treatment of chronic migraine. S.S. Korsakov Journal of Neurology and Psychiatry. 2011;111(5):85‑89. (In Russ.)

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Expe­rience of Rela­tox (botulinum toxin type A) using for chro­nic migraine treatment. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(12):134-140
Complexity index of microsurgical treatment of unru­ptured cere­bral aneurysms. Burdenko's Journal of Neurosurgery. 2025;(3):28-41
Prophylactic treatment of migraine in real clinical practice. Russian Journal of Pain. 2025;(2):63-69
Complexity index of endo­vascular treatment of unru­ptured cere­bral aneurysms. Burdenko's Journal of Neurosurgery. 2025;(4):39-50
Vascular endo­thelial growth factor in episodic and chro­nic migraine: new approaches to unde­rstanding pathogenesis. Russian Journal of Pain. 2025;(3):17-21
Abstract:

Keywords:

chronic migrane
chronic daily headache
preventive treatment

Authors:

Artemenko A.R.

Moskovskaia meditsinskaia akademiia im. I.M. Sechenova

Kurenkov A.L.

Nauchnyĭ tsentr zdorov'ia deteĭ RAMN

Nikitin S.S.

GU NII OPiPF RAMN, Moskva

Close metadata

References:

  1. Amelin A.V., Tarasova S.V., Ignatov Yu.D. i dr. Primenenie antidepressantov s razlichnym mekhanizmom deistviya pri khronicheskoi ezhednevnoi golovnoi boli. Zhurn nevrol i psikhiat 2007; 107: 9: 38-44.
  2. Amelin A.V., Tarasova S.V., Sokolov A.Yu. i dr. Effektivnost' raznykh antikonvul'santov pri khronicheskoi ezhednevnoi golovnoi boli. Zhurn nevrol i psikhiat 2007; 107: 1: 16-20.
  3. Artemenko A.R., Kurenkov A.L., Filatova E.G. Effektivnost' duloksetina pri lechenii khronicheskoi ezhednevnoi golovnoi boli. Zhurn nevrol i psikhiat 2007; 107: 8: 24-28.
  4. Artemenko A.R. Khronicheskaya migren': klinika, patogenez, lechenie: Avtoref. dis. … d-ra med. nauk. M 2010; 205.
  5. Artemenko A.R. Khronicheskie ezhednevnye golovnye boli: khronicheskaya migren' (stat'ya). Materialy I Rossiisko-Belorusskoi nauchno-prakticheskoi konferentsii po neirostomatologii "Bolevye sindromy v oblasti golovy, litsa i polosti rta". Smolensk 9-10 sentyabrya 2010; 115-124.
  6. Artemenko A.R., Kurenkov A.L., Mingazova L.R. i dr. Botulinoterapiya golovnykh i litsevykh bolei i miofastsial'nykh sindromov. Bolevye sindromy v nevrologicheskoi praktike. Pod red. V.L. Golubeva (3-e izdanie). M: MEDpress-inform 2010; 302-330.
  7. Artemenko A.R., Kurenkov A.L., Nikitin S.S., Filatova E.G. Duloksetin v lechenii khronicheskoi migreni. Zhurn nevrol i psikhiat 2010; 110: 1: 49-54.
  8. Nikitin S.S., Kurenkov A.L. Magnitnaya stimulyatsiya v diagnostike i lechenii boleznei nervnoi sistemy. Rukovodstvo dlya vrachei. M: SAShKO 2003; 387.
  9. Osipova V.V., Tabeeva G.R. Khronicheskaya migren': klinicheskaya kharakteristika, printsipy diagnostiki i terapii. Vrach 2007; 5: 24-26.
  10. Afridi S.K., Shields K.G., Bhola R., Goadsby P.J. Greater occipital nerve injection in primary headache syndromes-prolonged effects from a single injection. Pain 2006; 122: 1-2: 126-129.
  11. Almaraz A.C., Dilli E., Dodick D.W. Prophylactic agents do not influence the acute efficacy of transcranial magnetic stimulation in migraine with aura. Cephalalgia 2009; 29: Suppl 1: 17.
  12. Ashkenazi A., Matro R., Shaw J.W. et al. Greater occipital nerve block using local anesthetics alone or with triamcinolone for transformed migraine: a randomized comparative study. J Neurol Neurosurg Psychiat 2008; 79: 4: 415-417.
  13. Ashkenazi A., Silberstein S. Botulinum toxin type A for the treatment of headache: why we say yes. Arch Neurol 2008; 65: 1: 146-149.
  14. Aurora S.K. Spectrum of illness: understanding biological patterns and relationships in chronic migraine. Neurology 2009; 72: Suppl 5: 8-13.
  15. Aurora S.K., Dodick D.W., Turkel C.C. et al. PREEMPT 1 Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 2010; 30: 7: 793-803.
  16. Bartolini M., Silvestrini M., Taffi R. et al. Efficacy of topiramate and valproate in chronic migraine. Clin Neuropharmacol 2005; 28: 6: 277-279.
  17. Bigal M.E., Lipton R.B. When migraine progresses: transformed or chronic migraine. Expert Rev Neurother 2006; 6: 3: 297-306.
  18. Bigal M.E., Lipton R.B. The differential diagnosis of chronic daily headaches: an algorithm-based approach. J Headache Pain 2007; 8: 5: 263-272.
  19. Bigal M.E., Lipton R.B., Holland P.R., Goadsby P.J. Obesity, migraine, and chronic migraine: possible mechanisms of interaction. Neurology 2007; 68: 21: 1851-1861.
  20. Blumenfeld A.M., Schim J.D., Chippendale T.J. Botulinum toxin type A and divalproex sodium for prophylactic treatment of episodic or chronic migraine. Headache 2008; 48: 2: 210-220.
  21. Blumenfeld A., Silberstein S.D., Dodick D.W. et al. Method of injection of onabotulinumtoxinA for chronic migraine: a safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program. Headache 2010; 50: 9: 1406-1418.
  22. Brandes J.L., Saper J.R., Diamond M. et al. MIGR-002 Study Group. Topiramate for migraine prevention: a randomized controlled trial. JAMA 2004; 291: 8: 965-973.
  23. Brighina F., Piazza A., Vitello G. et al. rTMS of the prefrontal cortex in the treatment of chronic migraine: a pilot study. J Neurol Sci 2004; 227: 1: 67-71.
  24. Briley M. Specific serotonin and noradrenalin reuptake inhibitors (SNRIs). A review of their pharmacology, clinical efficacy and tolerability. Human Psychopharmacol 1998; 13: 99-111.
  25. Cady R.K., Schreiber C.P., Porter J.A. et al. A Multi-Center Double-Blind Pilot Comparison of OnabotulinumtoxinA and Topiramate for the Prophylactic Treatment of Chronic Migraine. Headache 2010; 10: doi: 10.1111/j.1526-4610.2010.01796.x.
  26. Christie S.N., Giammarco R., Gawel M. et al. Botulinum toxin type A and acute drug costs in migraine with triptan overuse. Can J Neurol Sci 2010; 37: 5: 588-594.
  27. Colombo B., Annovazzi P.O.L., Comi G. Therapy of primary headache: the role of antiderassants. Neurol Sci 2004; 25: 171-175.
  28. Couch J.R. Amitriptyline in the Prophylactic Treatment of Migraine and Chronic Daily Headache. Headache. 2010; 10: doi: 10.1111/j.1526-4610. 2010.01800.
  29. DAmico D., Usai S., Grazzi L. et al. Quality of life and disability in primary chronic daily headaches. Neurol Sci 2003; 24: Suppl 2: 97-100.
  30. DAmico D. Pharmacological prophylaxis of chronic migraine: a review of double-blind placebo-controlled trials. Neurol Sci 2010; 31: Suppl 1: 23-28.
  31. de Tommaso M., Sardaro M., Vecchio E. et al. Central sensitisation phenomena in primary headaches: overview of a preventive therapeutic approach. CNS Neurol Disord Drug Targets 2008; 7: 6: 524-535.
  32. Diener H.C., Bussone G., Van Oene J.C. et al. TOPMAT-MIG-201(TOP-CHROME) Study Group. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia 2007; 27: 7: 814-823.
  33. Diener H.C., Dodick D.W., Goadsby P.J. et al. Utility of topiramate for the treatment of patients with chronic migraine in the presence or absence of acute medication overuse. Cephalalgia 2009; 29: 10: 1021-1027.
  34. Diener H.C., Dodick D.W., Aurora S.K. et al. PREEMPT 2 Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 2010; 30: 7: 804-814.
  35. Dodick D.W., Mauskop A., Elkind A.H. et al. Botulinum toxin type A for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study. Headache 2005; 45: 4: 315-324.
  36. Dodick D.W. Chronic daily headache. N Engl J Med 2006; 354: 158-164.
  37. Dodick D.W., Silberstein S., Saper J. et al. The impact of topiramate on health-related quality of life indicators in chronic migraine. Headache 2007; 47: 10: 1398-1408.
  38. Dodick D.W., Smith T.R., Becker W.J. et al. Botulinum neurotoxin type A for treatment of chronic migraine: PREEMPT 2 trial double-blind phase. Cephalalgia 2009; 29: Suppl 1: 29.
  39. Dressler D., Saberi F.A., Barbosa E.R. Botulinum toxin: mechanisms of action. Arq Neuropsiquiat 2005; 63: 180-185.
  40. Edwards M.J., Talelli P., Rothwell J.C. Clinical applications of transcranial magnetic stimulation in patients with movement disorders. Lancet Neurol 2008; 7: 9: 827-840. Fischell R., Upton A. Cortical stimulation in migraine and epilepsy. Brain stimulation: superficial and deep, old and new. 102nd ICB seminar, Warsawa, Poland, May 11-13, 2009; 18.
  41. Fontebasso M. Topiramate for migraine prophylaxis. Expert Opin Pharmacother 2007; 8: 16: 2811-2823.
  42. Freitag F.G., Diamond S., Diamond M., Urban G. Botulinum Toxin Type A in the treatment of chronic migraine without medication overuse. Headache 2008; 48: 2: 201-209.
  43. Grazzi L., Andrasik F., DAmico D. et al. Behavioral and pharmacologic treatment of transformed migraine with analgesic overuse: outcome at 3 years. Headache 2002; 42: 6: 483-490.
  44. Headache Classification Subcommittee, International Headache Society. The international classification of headache disorders, 2nd edition. Cephalalgia 2004; 24: Suppl 1: 1-160.
  45. Olesen J., Bousser M.G. et al. Headache Classification Committee. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia 2006; 26: 6: 742-746.
  46. Horst W.D., Preskorn S.H. Mechanisms of action and clinical characteristics of three atypical antidepressants: venlafaxine, nefazodone, bupropion. J Affect Disord 1998; 51: 237-254.
  47. Jakubowski M., McAllister P.J., Bajwa Z.H. et al. Exploding vs. imploding headache in migraine prophylaxis with Botulinum Toxin A. Pain 2006; 125: 3: 286-295.
  48. Jasper J., Hayek S. Implanted occipital nerve stimulators. Pain Physician 2008; 11: 187-200.
  49. Krymchantowski A.V., Silva M.T., Barbosa J.S., Alves L.A. Amitriptyline versus amitriptyline combined with fluoxetine in the preventative treatment of transformed migraine: a double-blind study. Headache 2002; 42: 510-514.
  50. Lefaucheur J.P. The use of repetitive transcranial magnetic stimulation (rTMS) in chronic neuropathic pain. Neurophysiol Clin 2006; 36: 3: 117-124.
  51. Lenaerts M.E., Oommen K.J., Couch J.R., Skaggs V. Can vagus nerve stimulation help migraine? Cephalalgia 2008; 28: 4: 392-395.
  52. Limmroth V., Biondi D., Pfeil J., Schwalen S. Topiramate in patients with episodic migraine: reducing the risk for chronic forms of headache. Headache 2007; 47: 1: 13-21.
  53. Lipton R.B., Varon S., Grosberg B. et al. Botulinum neurotoxin type A treatment improves health-related quality of life and reduces impact of chronic migraine: results from the double-blind phase of the PREEMPT clinical program. Cephalalgia 2009; 29: Suppl 1: 32.
  54. Magalhães E., Menezes C., Cardeal M., Melo A. Botulinum toxin type A versus amitriptyline for the treatment of chronic daily migraine. Clin Neurol Neurosurg 2010; 112: 6: 463-466.
  55. Mathew N.T., Frishberg B.M., Gawel M. et al. BOTOX CDH Study Group. Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Headache 2005; 45: 4: 293-307.
  56. Mathew N.T. The prophylactic treatment of chronic daily headache. Headache 2006; 46: 10: 1552-1564.
  57. Mathew N.T. A double-blind comparison of botulinum toxin type A (BoNTA) and topiramate for the prophylactic treatment of transformed migraine headaches: a pilot study. Presented at the 12th Congress of European Federation of Neurological Societies; August 23-26, 2008 Madrid, Spain.
  58. Mathew N.T., Kailasam J., Meadors L. Predictors of response to botulinum toxin type A (BoNTA) in chronic daily headache. Headache 2008; 48: 2: 194-200.
  59. Mathew N.T. Dynamic optimization of chronic migraine treatment: current and future options. Neurology 2009; 72: Suppl 5: 14-20.
  60. Mei D., Capuano A., Vollono C. et al. Topiramate in migraine prophylaxis: a randomised double-blind versus placebo study. Neurol Sci 2004; 25: 5: 245-250.
  61. Menezes C., Rodrigues B., Magalhães E., Melo A. Botulinum toxin type A in refractory chronic migraine: an open-label trial. Arq Neuropsiquiat 2007; 65: 3A: 596-598.
  62. Mulleners W.M., Chronicle E.P. Anticonvulsants in migraine prophylaxis: a Cochrane review. Cephalalgia 2008; 28: 6: 585-597.
  63. Naegel S., Obermann M. Topiramate in the prevention and treatment of migraine: efficacy, safety and patient preference. Neuropsychiatr Dis Treat 2010; 6: 17-28.
  64. Negro A., DAlonzo L., Martelletti P. Chronic migraine: comorbidities, risk factors, and rehabilitation. Intern Emerg Med 2010; 5: Suppl 1: 13-19.
  65. Ozyalcin S.N., Talu G.K., Kiziltan E. et al. The efficacy and safety of venlafaxine in the prophylaxis of migraine. Headache 2005; 45: 144-152.
  66. Pascual J., Leira R., Láinez J.M. Combined therapy for migraine prevention? Clinical experience with a beta-blocker plus sodium valproate in 52 resistant migraine patients. Cephalalgia 2003; 23: 10: 961-962.
  67. Pascual J., Rivas M.T., Leira R. Testing the combination beta-blocker plus topiramate in refractory migraine. Acta Neurol Scand 2007; 115: 2: 81-83.
  68. Peres M.F., Mercante J.P., Tanuri F.C. et al. Chronic migraine prevention with topiramate. J Headache Pain 2006; 7: 4: 185-187.
  69. Saper J.R., Silberstein S.D., Lake A.E., Winters M.E. Double-blind trial of fluoxetine: chronic daily headache and migraine. Headache 1994; 34: 9: 497-502.
  70. Saper J.R., Lake A.E., Cantrell D.T. et al. Chronic daily headache prophylaxis with tizanidine: a double-blind, placebo-controlled, multicenter outcome study. Headache 2002; 42: 6: 470-482.
  71. Scher A.I., Stewart W.F., Liberman J., Lipton R.B. Prevalence of frequent headache in a population sample. Headache 1998; 38: 497-506.
  72. Scher A.I., Lipton R.B., Stewart W.F. Habitual snoring as a risk factor for chronic daily headache. Neurology 2003; 60: 8: 1366-1368.
  73. Scher A.I., Stewart W.F., Ricci J.A., Lipton R.B. Factors associated with the onset and remission of chronic daily headache in a population-based study. Pain 2003; 106: 1-2: 81-89.
  74. Scher A.I., Stewart W.F., Lipton R.B. Caffeine as a risk factor for chronic daily headache: a population-based study. Neurology 2004; 63: 11: 2022-2027.
  75. Schoenen J., Allena M., Magis D. Neurostimulation therapy in intractable headaches. Handb Clin Neurol 2010; 97: 443-450.
  76. Silberstein S.D., Lipton R.B., Solomon S., Mathew N.T. Classification of daily and near daily headaches: proposed revisions to the HIS classification. Headache 1994; 34: 1-7.
  77. Silberstein S.D., Stark S.R., Lucas S.M. et al. Botulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 2005; 80: 9: 1126-1137.
  78. Silberstein S.D., Lipton R.B., Dodick D.W. et al. Topiramate Chronic Migraine Study Group. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache 2007; 47: 2: 170-180.
  79. Silberstein S., Tfelt-Hansen P., Dodick D.W. et al. Task Force of the International Headache Society Clinical Trials Subcommittee. Guidelines for controlled trials of prophylactic treatment of chronic migraine in adults. Cephalalgia 2008; 28: 5: 484-495.
  80. Silberstein S., Lipton R., Dodick D. et al. Topiramate treatment of chronic migraine: a randomized, placebo-controlled trial of quality of life and other efficacy measures. Headache 2009; 49: 8: 1153-1162.
  81. Silvestrini M., Bartolini M., Coccia M. et al. Topiramate in the treatment of chronic migraine. Cephalalgia 2003; 23: 8: 820-824.
  82. Spira P.J., Beran R.G. Australian Gabapentin Chronic Daily Headache Group. Gabapentin in the prophylaxis of chronic daily headache: a randomized, placebo-controlled study. Neurology 2003; 61: 12: 1753-1759.
  83. Teepker M., Hötzel J., Timmesfeld N. et al. Low-frequency rTMS of the vertex in the prophylactic treatment of migraine. Cephalalgia 2010; 30: 2: 137-144.
  84. Tronnier V., Rasche D. Subcutaneous peripheral stimulation of the greater occipital nerve for the treatment of chronic headache syndromes. Schmerz 2010; 24: 5: 441-448.
  85. Volpe F.M. An 8-week, open-label trial of duloxetine for comorbid major depressive disorder and chronic headache. J Clin Psychiat 2008; 69: 9: 1449-1454.
  86. Wiendels N.J., van Haestregt A., Knuistingh Neven A. et al. Chronic frequent headache in the general population: comorbidity and quality of life. Cephalalgia 2006; 26: 12: 1443-1450.
  87. Yurekli V.A., Akhan G., Kutluhan S. et al. The effect of sodium valproate on chronic daily headache and its subgroups. J Headache Pain 2008; 9: 1: 37-41.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.